315 related articles for article (PubMed ID: 32164474)
1. Cabotegravir and rilpivirine for the treatment of HIV.
Rial-Crestelo D; Pinto-Martínez A; Pulido F
Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
[No Abstract] [Full Text] [Related]
2. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
[No Abstract] [Full Text] [Related]
3. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
[TBL] [Abstract][Full Text] [Related]
4. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
6. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
7. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
8. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
Kovač L; Časar Z
Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
[No Abstract] [Full Text] [Related]
9. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
[TBL] [Abstract][Full Text] [Related]
12. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
14. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
[TBL] [Abstract][Full Text] [Related]
18. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
[TBL] [Abstract][Full Text] [Related]
19. Cabotegravir Plus Rilpivirine: First Approval.
Markham A
Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
Qazzaz H; Parganas C; Cory TJ
Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
